文献速递精神分裂症与精神病性障碍

抗精神病药剂量、多巴胺D2受体占用与锥体外系副作用的剂量反应荟萃分析

Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis.
PubMed 文献 · Mol Psychiatry · 2023-08-03

该系统综述与剂量反应荟萃分析纳入110项固定剂量研究(382个剂量组,37193名精神分裂症急性加重成人患者),评估16种第二代抗精神病药与氟哌啶醇的锥体外系副作用(EPS)风险。几乎所有药物均呈剂量依赖性EPS风险,最大OR从阿立哌唑1.57至氟哌啶醇30 mg/d的7.56不等,喹硫平和舍吲哚在各剂量下风险可忽略;D2受体占用超过75-85%时风险显著增加,但D2部分激动剂例外。

要点

  • 几乎所有抗精神病药EPS风险随剂量增加,氟哌啶醇30 mg/d的OR最高达7.56。
  • 喹硫平和舍吲哚在所有剂量下EPS风险可忽略。
  • D2受体占用超过75-85%时EPS风险显著增加,D2部分激动剂例外。

核心结论

  • 抗精神病药EPS风险随剂量增加而上升,不同药物间幅度差异大,喹硫平和舍吲哚例外。
  • D2受体占用超过75-85%时EPS风险显著增加,D2部分激动剂在高占用下OR较小。

研究设计与样本

  • 系统综述与剂量反应荟萃分析,检索多个电子数据库至2023年2月20日。
  • 纳入110项固定剂量研究,382个剂量组,37193名精神分裂症急性加重成人患者。
  • 评估16种第二代抗精神病药与氟哌啶醇,主要结局为接受抗帕金森病药物的人数。

主要发现

  • 几乎所有抗精神病药均与剂量依赖性EPS相关,最大OR从阿立哌唑1.57(95%CI 0.97-2.56)到氟哌啶醇30 mg/d的7.56(95%CI 3.16-18.08)。
  • 喹硫平和舍吲哚在所有剂量下风险可忽略。
  • 卡利拉嗪、伊潘立酮和佐替平证据质量极低,氯氮平无数据。
  • D2受体占用曲线显示超过75-85%时风险显著增加,D2部分激动剂例外。

关键数值与推荐

  • 主要结局为接受抗帕金森病药物的人数,否则以EPS人数或EPS评定量表平均分替代。
  • 效应量为与安慰剂比较的比值比(OR)。
  • 采用单阶段随机效应剂量反应荟萃分析及限制性立方样条估计剂量反应曲线。
  • 通过给药剂量估算D2受体占用,检验其与OR的关系。

临床怎么用

  • 临床处方抗精神病药时应考虑剂量依赖性EPS风险,尤其高剂量氟哌啶醇。
  • 喹硫平和舍吲哚在各剂量下EPS风险可忽略,可作为低EPS风险选择。
  • D2受体占用超过75-85%时EPS风险增加,D2部分激动剂可能具有更宽的安全窗口。

局限性

  • 大多数研究为短期,中位持续时间6周(范围3-26周)。
  • 卡利拉嗪、伊潘立酮和佐替平证据质量极低,氯氮平无数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antipsychotic drugs differ in their propensity to cause extrapyramidal side-effects (EPS), but their dose-effects are unclear. Therefore, we conducted a systematic review and dose-response meta-analysis. We searched multiple electronic databases up to 20.02.2023 for fixed-dose studies investigating 16 second-generation antipsychotics and haloperidol (all formulations and administration routes) in adults with acute exacerbations of schizophrenia. The primary outcome was the number of participants receiving antiparkinsonian medication, and if not available, the number of participants with extrapyramidal side-effects (EPS) and the mean scores of EPS rating scales were used as proxies. The effect-size was odds ratio (ORs) compared with placebo. One-stage random-effects dose-response meta-analyses with restricted cubic splines were conducted to estimate the dose-response curves. We also examined the relationship between dopamine D2 receptor (D2R) occupancy and ORs by estimating occupancies from administrated doses. We included data from 110 studies with 382 dose arms (37193 participants). Most studies were short-term with median duration of 6 weeks (range 3-26 weeks). Almost all antipsychotics were associated with dose-dependent EPS with varied degrees and the maximum ORs ranged from OR = 1.57 95%CI [0.97, 2.56] for aripiprazole to OR = 7.56 95%CI [3.16, 18.08] for haloperidol at 30 mg/d. Exceptions were quetiapine and sertindole with negligible risks across all doses. There was very low quality of findings for cariprazine, iloperidone, and zotepine, and no data for clozapine. The D2R occupancy curves showed that the risk increased substantially when D2R occupancy exceeded 75-85%, except for D2R partial agonists that had smaller ORs albeit high D2R occupancies. In conclusion, we found that the risk of EPS increases with rising doses and differs substantially in magnitude among antipsychotics, yet exceptions were quetiapine and sertindole with negligible risks. Our data provided additional insights into the current D2R therapeutic window for EPS.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Siafis S, Wu H, Wang D, et al. Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. Mol Psychiatry. 2023. PMID: 37537284. doi:10.1038/s41380-023-02203-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。